FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129132730> ?p ?o ?g. }

• W2129132730 endingPage "2576" @default.
• W2129132730 startingPage "2567" @default.
• W2129132730 abstract "Background— Lipoprotein(a) (Lp(a)) hyperlipoproteinemia is a major risk factor for cardiovascular disease, which is not affected by treatment of other cardiovascular risk factors. This study sought to assess the effect of chronic lipoprotein apheresis (LA) on the incidence of cardiovascular events in patients with progressive cardiovascular disease receiving maximally tolerated lipid-lowering treatment. Methods and Results— In a prospective observational multicenter study, 170 patients were investigated who commenced LA because of Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease. Patients were characterized regarding plasma lipid status, lipid-lowering drug treatment, and variants at the LPA gene locus. The incidence rates of cardiovascular events 2 years before (y-2 and y-1) and prospectively 2 years during LA treatment (y+1, y+2) were compared. The mean age of patients was 51 years at the first cardiovascular event and 57 years at the first LA. Before LA, mean low-density lipoprotein cholesterol and Lp(a) were 2.56±1.04 mmol·L −1 (99.0±40.1 mg·dL −1 ) and Lp(a) 3.74±1.63 µmol·L −1 (104.9±45.7 mg·dL −1 ), respectively. Mean annual rates for major adverse coronary events declined from 0.41 for 2 years before LA to 0.09 for 2 years during LA ( P <0.0001). Event rates including all vascular beds declined from 0.61 to 0.16 ( P <0.0001). Analysis of single years revealed increasing major adverse coronary event rates from 0.30 to 0.54 ( P =0.001) for y-2 to y-1 before LA, decline to 0.14 from y-1 to y+1 ( P <0.0001) and to 0.05 from y+1 to y+2 ( P =0.014). Conclusions— In patients with Lp(a)-hyperlipoproteinemia, progressive cardiovascular disease, and maximally tolerated lipid-lowering medication, LA effectively lowered the incidence rate of cardiovascular events. Clinical Trial Registration— URL: https://drks-neu.uniklinik-freiburg.de . Unique identifier: DRKS00003119." @default.
• W2129132730 created "2016-06-24" @default.
• W2129132730 creator A5001702434 @default.
• W2129132730 creator A5022996948 @default.
• W2129132730 creator A5028478397 @default.
• W2129132730 creator A5045083999 @default.
• W2129132730 creator A5047902528 @default.
• W2129132730 creator A5048372741 @default.
• W2129132730 creator A5063386957 @default.
• W2129132730 creator A5073390275 @default.
• W2129132730 creator A5077027018 @default.
• W2129132730 creator A5079325211 @default.
• W2129132730 creator A5080659719 @default.
• W2129132730 date "2013-12-17" @default.
• W2129132730 modified "2023-10-13" @default.
• W2129132730 title "Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease" @default.
• W2129132730 cites W1983260286 @default.
• W2129132730 cites W1984222785 @default.
• W2129132730 cites W1992969017 @default.
• W2129132730 cites W2032329599 @default.
• W2129132730 cites W2036170644 @default.
• W2129132730 cites W2088794717 @default.
• W2129132730 cites W2098230963 @default.
• W2129132730 cites W2098890974 @default.
• W2129132730 cites W2104355263 @default.
• W2129132730 cites W2114560428 @default.
• W2129132730 cites W2116478762 @default.
• W2129132730 cites W2154341125 @default.
• W2129132730 doi "https://doi.org/10.1161/circulationaha.113.002432" @default.
• W2129132730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24056686" @default.
• W2129132730 hasPublicationYear "2013" @default.
• W2129132730 type Work @default.
• W2129132730 sameAs 2129132730 @default.
• W2129132730 citedByCount "263" @default.
• W2129132730 countsByYear W21291327302013 @default.
• W2129132730 countsByYear W21291327302014 @default.
• W2129132730 countsByYear W21291327302015 @default.
• W2129132730 countsByYear W21291327302016 @default.
• W2129132730 countsByYear W21291327302017 @default.
• W2129132730 countsByYear W21291327302018 @default.
• W2129132730 countsByYear W21291327302019 @default.
• W2129132730 countsByYear W21291327302020 @default.
• W2129132730 countsByYear W21291327302021 @default.
• W2129132730 countsByYear W21291327302022 @default.
• W2129132730 countsByYear W21291327302023 @default.
• W2129132730 crossrefType "journal-article" @default.
• W2129132730 hasAuthorship W2129132730A5001702434 @default.
• W2129132730 hasAuthorship W2129132730A5022996948 @default.
• W2129132730 hasAuthorship W2129132730A5028478397 @default.
• W2129132730 hasAuthorship W2129132730A5045083999 @default.
• W2129132730 hasAuthorship W2129132730A5047902528 @default.
• W2129132730 hasAuthorship W2129132730A5048372741 @default.
• W2129132730 hasAuthorship W2129132730A5063386957 @default.
• W2129132730 hasAuthorship W2129132730A5073390275 @default.
• W2129132730 hasAuthorship W2129132730A5077027018 @default.
• W2129132730 hasAuthorship W2129132730A5079325211 @default.
• W2129132730 hasAuthorship W2129132730A5080659719 @default.
• W2129132730 hasBestOaLocation W21291327301 @default.
• W2129132730 hasConcept C120665830 @default.
• W2129132730 hasConcept C121332964 @default.
• W2129132730 hasConcept C126322002 @default.
• W2129132730 hasConcept C164705383 @default.
• W2129132730 hasConcept C188816634 @default.
• W2129132730 hasConcept C197934379 @default.
• W2129132730 hasConcept C2776104379 @default.
• W2129132730 hasConcept C2778163477 @default.
• W2129132730 hasConcept C2778213512 @default.
• W2129132730 hasConcept C2779120738 @default.
• W2129132730 hasConcept C2780072125 @default.
• W2129132730 hasConcept C50440223 @default.
• W2129132730 hasConcept C61511704 @default.
• W2129132730 hasConcept C71924100 @default.
• W2129132730 hasConcept C90924648 @default.
• W2129132730 hasConceptScore W2129132730C120665830 @default.
• W2129132730 hasConceptScore W2129132730C121332964 @default.
• W2129132730 hasConceptScore W2129132730C126322002 @default.
• W2129132730 hasConceptScore W2129132730C164705383 @default.
• W2129132730 hasConceptScore W2129132730C188816634 @default.
• W2129132730 hasConceptScore W2129132730C197934379 @default.
• W2129132730 hasConceptScore W2129132730C2776104379 @default.
• W2129132730 hasConceptScore W2129132730C2778163477 @default.
• W2129132730 hasConceptScore W2129132730C2778213512 @default.
• W2129132730 hasConceptScore W2129132730C2779120738 @default.
• W2129132730 hasConceptScore W2129132730C2780072125 @default.
• W2129132730 hasConceptScore W2129132730C50440223 @default.
• W2129132730 hasConceptScore W2129132730C61511704 @default.
• W2129132730 hasConceptScore W2129132730C71924100 @default.
• W2129132730 hasConceptScore W2129132730C90924648 @default.
• W2129132730 hasIssue "24" @default.
• W2129132730 hasLocation W21291327301 @default.
• W2129132730 hasLocation W21291327302 @default.
• W2129132730 hasOpenAccess W2129132730 @default.
• W2129132730 hasPrimaryLocation W21291327301 @default.
• W2129132730 hasRelatedWork W2020629107 @default.
• W2129132730 hasRelatedWork W2088880552 @default.
• W2129132730 hasRelatedWork W2108284872 @default.
• W2129132730 hasRelatedWork W2329533302 @default.
• W2129132730 hasRelatedWork W2411136260 @default.

• next